Tethering identifies fragment that yields potent inhibitors of human caspase-1.

Molecular docking and ligand specificity in fragment-based inhibitor discovery. Nat Chem Biol (2009) 1.60

Crystal structure of procaspase-1 zymogen domain reveals insight into inflammatory caspase autoactivation. J Biol Chem (2008) 1.26

Berkeleyones and related meroterpenes from a deep water acid mine waste fungus that inhibit the production of interleukin 1-β from induced inflammasomes. J Nat Prod (2011) 1.02

Small Molecule Active Site Directed Tools for Studying Human Caspases. Chem Rev (2015) 0.77

Discovery of an allosteric site in the caspases. Proc Natl Acad Sci U S A (2004) 2.51

A common allosteric site and mechanism in caspases. Proc Natl Acad Sci U S A (2006) 2.12

Fragment-based drug discovery. J Med Chem (2004) 2.07

Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci U S A (2011) 2.01

The cholesterol-regulated StarD4 gene encodes a StAR-related lipid transfer protein with two closely related homologues, StarD5 and StarD6. Proc Natl Acad Sci U S A (2002) 1.76

Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. Nat Chem Biol (2013) 1.65

Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases. Protein Sci (2010) 1.53

Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action. Angew Chem Int Ed Engl (2003) 1.39

An allosteric circuit in caspase-1. J Mol Biol (2008) 1.38

Crystal structures of a ligand-free and malonate-bound human caspase-1: implications for the mechanism of substrate binding. Structure (2004) 1.24

The kinetic mechanism of phosphomevalonate kinase. J Biol Chem (2002) 1.19

Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. J Med Chem (2005) 1.19

Discovery of a potent and selective aurora kinase inhibitor. Bioorg Med Chem Lett (2008) 1.15

Malonate-assisted purification of human caspases. Protein Expr Purif (2005) 1.12

In situ assembly of enzyme inhibitors using extended tethering. Nat Biotechnol (2003) 1.11

Crystal structure of unphosphorylated STAT3 core fragment. Biochem Biophys Res Commun (2008) 1.11

Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. J Am Chem Soc (2003) 1.11

Glycosaminoglycan mimetic biomaterials. 4. Synthesis of sulfated lactose-based glycopolymers that exhibit anticoagulant activity. Biomacromolecules (2002) 1.06

Screening transthyretin amyloid fibril inhibitors: characterization of novel multiprotein, multiligand complexes by mass spectrometry. Structure (2002) 1.03

Alkylsulfanyl-1,2,4-triazoles, a new class of allosteric valosine containing protein inhibitors. Synthesis and structure-activity relationships. J Med Chem (2013) 1.02

Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic stabilization of the native state. J Am Chem Soc (2005) 1.01

Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors. Bioorg Med Chem Lett (2008) 1.00

Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenase. Bioorg Med Chem Lett (2013) 0.94

Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900. Mol Cancer Ther (2013) 0.94

SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol (2009) 0.93

Fragment-based discovery of nonpeptidic BACE-1 inhibitors using tethering. Biochemistry (2009) 0.93

Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design. J Med Chem (2002) 0.92

Integrating fragment assembly and biophysical methods in the chemical advancement of small-molecule antagonists of IL-2: an approach for inhibiting protein-protein interactions. J Med Chem (2004) 0.92

Acylideneoxoindoles: a new class of reversible inhibitors of human transglutaminase 2. Bioorg Med Chem Lett (2010) 0.92

Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery. Bioorg Med Chem Lett (2011) 0.91

Design and synthesis of dimeric heparinoid mimetics. J Org Chem (2004) 0.90

Design, synthesis, and evaluation of oxazole transthyretin amyloidogenesis inhibitors. Bioorg Med Chem Lett (2005) 0.88

Structures of the wild-type and activated catalytic domains of Brachydanio rerio Polo-like kinase 1 (Plk1): changes in the active-site conformation and interactions with ligands. Acta Crystallogr D Biol Crystallogr (2008) 0.88

Inhibition of human papilloma virus E2 DNA binding protein by covalently linked polyamides. Nucleic Acids Res (2003) 0.86

2-Aminobenzimidazoles as potent Aurora kinase inhibitors. Bioorg Med Chem Lett (2009) 0.84

The relativity of time perception produced by facial emotion stimuli. Cogn Emot (2011) 0.83

Influence of number of CAG repeats on local control in the RTOG 86-10 protocol. Am J Clin Oncol (2006) 0.83

A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties. Bioorg Med Chem Lett (2008) 0.83

Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation. J Med Chem (2014) 0.82

Mouse Aurora A: expression in Escherichia coli and purification. Protein Expr Purif (2007) 0.81

Naturally occurring genetic variants of human caspase-1 differ considerably in structure and the ability to activate interleukin-1β. Hum Mutat (2012) 0.80

Structural analysis of caspase-1 inhibitors derived from Tethering. Acta Crystallogr Sect F Struct Biol Cryst Commun (2005) 0.80

Design and synthesis of 2-amino-isoxazolopyridines as Polo-like kinase inhibitors. Bioorg Med Chem Lett (2008) 0.79

Tissue levels of arsenicals and skin tumor response following administration of monomethylarsonous acid and arsenite to K6/ODC mice. J Environ Pathol Toxicol Oncol (2008) 0.79

Discovery of 7-tetrahydropyran-2-yl chromans: β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors that reduce amyloid β-protein (Aβ) in the central nervous system. J Med Chem (2014) 0.79

Towards a developmental framework of consumer and carer participation in child and adolescent mental health services. Australas Psychiatry (2007) 0.78

Diazinones as P2 replacements for pyrazole-based cathepsin S inhibitors. Bioorg Med Chem Lett (2010) 0.78

Identification of potent and novel small-molecule inhibitors of caspase-3. Bioorg Med Chem Lett (2003) 0.78

Optimization of 5-(2,6-dichlorophenyl)-3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase. Bioorg Med Chem Lett (2014) 0.78

Identification of new inhibitors of protein kinase R guided by statistical modeling. Bioorg Med Chem Lett (2011) 0.78

Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio. Bioorg Med Chem Lett (2008) 0.77

Structure of the Brachydanio rerio Polo-like kinase 1 (Plk1) catalytic domain in complex with an extended inhibitor targeting the adaptive pocket of the enzyme. Acta Crystallogr Sect F Struct Biol Cryst Commun (2008) 0.76

Direct hit. Nurses win with targeted ads. Revolution (2002) 0.75

Identification of nonpeptidic small-molecule inhibitors of interleukin-2. Bioorg Med Chem Lett (2005) 0.75

Water-soluble prodrugs of an Aurora kinase inhibitor. Bioorg Med Chem Lett (2009) 0.75

8-Tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors. J Med Chem (2014) 0.75

Chemoselective arylamidine cyclizations: mild formation of 2-arylimidazole-4-carboxylic acids. Org Lett (2005) 0.75

Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor. J Med Chem (2016) 0.75